Deximune 25, 50, 100 mg

/ Dexcel

For additional information, please contact the license holder.

Prophylaxis of organ rejection in kidney, liver, heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic  rejection in patients previously treated with other immuno-suppressive agents. Bone marrow transplantation. Endogenous uveitis. Severe psoriasis above age 16 that did not respond to other treatment. Atopic dermatitis in adults only up to 8 weeks, for severe cases in which conventional therapy is ineffective or inappropriate. Rheumatoid arthritis: Severe cases in which standard treatments are ineffective or inappropriate. Nephrotic syndrome type MCD (minimal change disease) in cases where conventional therapy has failed.

Breastfeeding. Hypersensitivity to one of the ingredients. Patients with atopic dermatitis or psoriasis who also suffer from impaired kidney function, unstable blood pressure, uncontrolled infections or any type of cancer, except certain skin tumors that require a biopsy prior to use of this medicine. Patients with rheumatoid arthritis who also suffer from impaired kidney function, unstable blood pressure, uncontrolled infections or any type of cancer, or in patients under 18 years of age. Concomitant administration of Deximun with the drugs tacrolimus or with rosuvastatin. Patients with nephrotic syndrome who also suffer from unstable blood pressure, uncontrolled infections or any type of cancer.

For additional information, please contact the license holder.

For additional information, please contact the license holder.

For additional information, please contact the license holder.

For additional information, please contact the license holder.

For additional information, please contact the license holder.